Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | KIF11 | P52732 | 2/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9453957 | 0.88 | CDK1 (0.68) | MAPTKDM4EKIF11CDK1ALDH1A1 | |
| SCHEMBL455344 | 0.83 | IDO1 (0.78) | IDO1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL5438060 | 0.81 | IDO1 (0.70) | IDO1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL18031170 | 0.81 | GAA (0.69) | MAPTKDM4EKIF11CDK1ALDH1A1 | |
| SCHEMBL462576 | 0.81 | IDO1 (0.58) | IDO1MAPTKDM4EKIF11ALDH1A1 | |
| SCHEMBL17956747 | 0.81 | KMT2A (0.69) | MAPTKDM4EKIF11CDK1ALDH1A1 | |
| SCHEMBL12412636 | 0.81 | L3MBTL1 (0.62) | MAPTKIF11CDK1ALDH1A1MEN1 | |
| SCHEMBL525759 | 0.80 | KIF11 (0.89) | KIF11CDK1ALDH1A1MEN1KMT2A | |
| SCHEMBL26156209 | 0.79 | GAA (0.63) | MAPTKIF11CDK1ALDH1A1MEN1 | |
| SCHEMBL11057676 | 0.79 | KIF11 (0.63) | IDO1MAPTKIF11CDK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010896-A | Bicyclol derivative, pharmaceutical composition thereof, preparation method and application thereof | 中国医学科学院药物研究所 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025046420-A1 | COMPOUND TARGETING EGR-1 AND USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS | 주식회사 아제라메디 | 2025-03-06 | — | — | WO | disclosed |
| CN-117645560-A | Ferulic acid derivative containing amide and preparation method and application thereof | 贵州大学 | 2024-03-05 | — | — | CN | disclosed |
| CN-114195691-B | Ferulic acid derivative containing amide and preparation method and application thereof | 贵州大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-114195691-A | Amide-containing ferulic acid derivative and preparation method and application thereof | 贵州大学 | 2022-03-18 | — | — | CN | disclosed |
| US-10975048-B2 | Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity | HANGZHOU JENNIFER BIOTECH CO LTD (CN) | 2021-04-13 | — | — | US | disclosed |
| EP-2240175-B1 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | US GOV HEALTH & HUMAN SERV (US) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012033601-A1 | THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20100316655-A1 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) | 2010-12-16 | — | — | US | disclosed |
| EP-2240175-A2 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102433-A2 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-4871737-A | 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0315433-A2 | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4826866-A | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975048-B2 | Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity | GPX4, GPX1, SELENOI | IDO1 2150/4885MAPT 3810/4885KDM4E 3993/4885 |
| US-20100316655-A1 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | ABCC1, ABCB1, ABCC2 | IDO1 4305/4885MAPT 4584/4885KDM4E 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.